Citations 2
Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis
Kazemi, Mir Salar, Kazemi-Lomedasht, Fatemeh, Mahjoobi, Golnoosh, Safi, Sare , Ashrafi, Sadra , Ahmadieh, Hamid, Shoari, Alireza , Kazemi-Lomedasht, Fatemeh , Kanavi, Mozhgan Rezaei , Cohan, Reza Ahangari , Ahmadieh, Hamid , Behdani, Mahdi
Biomolecules | May 25, 2026 | Volume: 16 | Issue: 6 | Pages: 772
Current treatments for choroidal neovascularization (CNV) and its associated subretinal fibrosis (SRF), major causes of vision loss, are limited by the need for frequent intravitreal injections and the emergence of drug resistance. This study evaluated the safety and efficacy of the intravitreal administration of engineered humanized anti-vascular endothelial growth factor Nanobodies, including a wild-type Nanobody (WHNb) and two mutated variants (MHNb136 and MHNb256), in a rat model of laser-induced CNV and associated SRF. Safety was assessed through in vivo electrophysiological and histopathological analyses following intravitreal injection of Nanobodies at doses of 12.5, 25, 50, and 100 µg. Efficacy was evaluated in rat models of laser-induced CNV and SRF using double immunohistochemistry for isolectin B4 and anti-collagen type I on sclerochoroidal flat mounts. Mean CNV and SRF areas in Nanobody-treated groups were compared with those in bevacizumab-treated and sham control groups. None of the Nanobodies showed retinal toxicity in safety assessments. Compared with bevacizumab, MHNb136 and MHNb256 reduced the CNV area by 1.72-fold and 1.8-fold, respectively (both p < 0.0001), whereas WHNb showed an effect nearly identical to that of bevacizumab. In addition, 12.5 µg MHNb136 and 100 µg MHNb256 reduced the SRF area by 1.3-fold (p = 0.047) and 1.6-fold (p = 0.0007), respectively, relative to bevacizumab. For CNV reduction, 12.5 µg MHNb136 was comparable to 25 µg MHNb256; both outperformed bevacizumab. For SRF reduction, 12.5 µg MHNb136 was more effective than bevacizumab and comparable to 100 µg MHNb256. These findings suggest that 12.5 µg MHNb136 may represent a cost-effective bioengineered Nanobody candidate for future clinical studies.
Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
Mansour, Ahmad M. , Arévalo, J. Fernando , Kahtani, Eman Al, Zegarra, Hernando, Abboud, Emad B. , Anand, Rajiv, Ahmadieh, Hamid , Mirza, Salman, Tuncer, Samuray , Návea, Amparo , Mataix, J. , Ascaso, Francisco J., Pulido, José S. , Guthoff, Rainer , Goebel, Winfried, Banker, Alay , Gentile, Ronald C., Martinez, Isabel Alonso, Morris, Rodney J, Panday, Neeraj, Min, Park Jung, Mercé, Emilie, Lai, Timothy Y. Y. , Massoud, Vicky, Ghazi, Nicola G. , Abboud, Emad , Sisk, Robert A. , Roh, Young‐Jung , Martínez, Isabel Alonso, Massoud, Vicky A., Arevalo, Jose Fernando
Journal of Ophthalmology | July 23, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-8
We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n=15;P=0.001), 105.3 microns at 1 year (n=10;P=0.03), and 157.6 microns at 2 years (n=7;P=0.08). BCVA improved by 3.3 lines at 6 months after therapy (n=26;P<0.001), 2.8 lines (n=20;P=0.01) at 1 year, and 3.1 lines (n=13;P=0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.